J&J’s COVID-19 vaccine could be authorised for emergency use as early as the beginning of 2021

Johnson and Johnson (J&J) has been developing a vaccine for the coronavirus and they have revealed that they will commence clinical trials in September. Furthermore, J&J has stated that if efficacy data is available by the end of 2020, the vaccine could be authorised for emergency use as early as the beginning of 2021.

In addition, J&J has received federal backing from the US, to increase manufacturing for the vaccine, to make a billion doses available globally.

The Biomedical Advanced Research and Development Authority (BARDA) and J&J have collectively invested one billion dollars into the vaccine project to be spent on clinical testing and development.

Alex Gorsky, J&J’s Chief Executive Officer, stated: “The world is facing an urgent public health crisis and we are committed to doing our part to make a COVID-19 vaccine available and affordable globally as quickly as possible.”